title: Metabolic syndrome in breast cancer.
abstract: Breast Cancer is a heterogeneous disease, progressive, currently, are classified according to in pattern of gene expression luminal A, luminal B, basal and HER-2neu + and Triple-negative, 75% to 80% have receptors positive hormonal and 15% to 20% are positive for hER-2neu and 10% to 20% are triple negative, with hormone receptor negative and HER2-neu and their diagnostic is made by exclusion, the Metabolic Syndrome is related to a higher incidence of these cancers where the insulin-leptin axis-adiponectin are implicated in carcinogenesis.
authors.affiliation: Investigations Division, Hospital Juárez de México, México city, México.
authors.forename: Víctor Manuel
authors.initials: VM
authors.lastname: Vargas-Hernández
authors.affiliation: Investigations Division, Hospital Juárez de México, México city, México.
authors.forename: Vm
authors.initials: V
authors.lastname: Vargas-Aguilar
authors.affiliation: Investigations Division, Hospital Juárez de México, México city, México.
authors.forename: Mario Adanm
authors.initials: MA
authors.lastname: Moreno-Eutimio
authors.affiliation: Investigations Division, Hospital Juárez de México, México city, México.
authors.forename: Gustavo
authors.initials: G
authors.lastname: Acosta-Altamirano
authors.affiliation: Investigations Division, Hospital Juárez de México, México city, México.
authors.forename: Jm
authors.initials: J
authors.lastname: Tovar-Rodriguez
keywords: Breast cancer; adiponectin; carcinogenesis; diabetes mellitus; growth factors; leptin; metabolic syndrome; triple negative breast cancer
references.citation: JAMA. 2007 Jul 18;298(3):289-98
references.pmid: 17635889
references.citation: Cancer. 2007 May 1;109(9):1721-8
references.pmid: 17387718
references.citation: Fertil Steril. 2002 Mar;77(3):433-44
references.pmid: 11872190
references.citation: JAMA. 2005 May 25;293(20):2479-86
references.pmid: 15914748
references.citation: Circ Res. 2005 Apr 29;96(8):838-46
references.pmid: 15790954
references.citation: Cell Cycle. 2009 Jul 1;8(13):2031-40
references.pmid: 19440038
references.citation: J Clin Oncol. 2011 Jan 1;29(1):25-31
references.pmid: 21115856
references.citation: J Natl Cancer Inst. 2006 Dec 20;98(24):1767-76
references.pmid: 17179478
references.citation: Breast Cancer Res Treat. 2010 Jun;121(2):479-83
references.pmid: 19851862
references.citation: JAMA. 2006 Jun 7;295(21):2492-502
references.pmid: 16757721
references.citation: J Clin Oncol. 2008 Sep 1;26(25):4072-7
references.pmid: 18757321
references.citation: Int J Cancer. 2007 Aug 15;121(4):856-62
references.pmid: 17397032
references.citation: Br J Cancer. 2004 Jun 1;90(11):2138-41
references.pmid: 15150561
references.citation: Cancer. 2011 Sep 15;117(18):4132-40
references.pmid: 21387276
references.citation: J Clin Oncol. 2012 Jan 10;30(2):164-71
references.pmid: 22162568
references.citation: J Hypertens. 2000 Mar;18(3):249-54
references.pmid: 10726709
references.citation: Diabetes Care. 2012 Feb;35(2):299-304
references.pmid: 22266734
references.citation: J Clin Oncol. 2008 Aug 20;26(24):3958-64
references.pmid: 18711185
references.citation: Obes Rev. 2003 Aug;4(3):157-73
references.pmid: 12916817
references.citation: J Clin Endocrinol Metab. 2007 Mar;92(3):1041-8
references.pmid: 17192291
references.citation: J Clin Oncol. 2010 Oct 10;28(29):4410-6
references.pmid: 20805458
references.citation: Diabetologia. 2011 Sep;54(9):2254-62
references.pmid: 21614572
references.citation: Cancer. 2006 Oct 15;107(8):1777-85
references.pmid: 16967443
references.citation: Lancet. 2008 Feb 16;371(9612):569-78
references.pmid: 18280327
references.citation: Breast Cancer Res. 2011 Mar 30;13(2):R34
references.pmid: 21450081
references.citation: Eur J Cancer. 2011 Jul;47(10):1578-84
references.pmid: 21353530
references.citation: Eur J Cancer. 2011 Jan;47(1):33-43
references.pmid: 20889333
references.citation: J Clin Oncol. 2011 Jan 1;29(1):54-60
references.pmid: 21115861
references.citation: Cancer. 2007 Aug 15;110(4):876-84
references.pmid: 17620276
references.citation: Breast Cancer Res. 2011 Mar 11;13(2):R30
references.pmid: 21396117
references.citation: J Clin Oncol. 2012 Jan 10;30(2):124-6
references.pmid: 22162567
references.citation: BMJ. 2005 Jun 4;330(7503):1304-5
references.pmid: 15849206
references.citation: Neoplasia. 2011 Jun;13(6):504-15
references.pmid: 21677874
references.citation: Hum Pathol. 2004 Dec;35(12):1537-42
references.pmid: 15619214
references.citation: Int J Cancer. 2009 Dec 1;125(11):2704-10
references.pmid: 19588485
references.citation: J Clin Oncol. 2011 Jan 1;29(1):47-53
references.pmid: 21115859
references.citation: J Clin Oncol. 2011 Apr 20;29(12):1592-8
references.pmid: 21422422
references.citation: J Clin Oncol. 2011 Jan 1;29(1):32-9
references.pmid: 21115858
references.citation: Cancer Cell. 2012 Jan 17;21(1):82-91
references.pmid: 22264790
references.citation: J Clin Oncol. 2005 Oct 10;23(29):7350-60
references.pmid: 16145060
references.citation: Clin Cancer Res. 2008 Mar 1;14(5):1368-76
references.pmid: 18316557
references.citation: J Clin Oncol. 2011 Jul 1;29(19):2645-52
references.pmid: 21632501
references.citation: Cell Cycle. 2009 Mar 15;8(6):909-15
references.pmid: 19221498
references.citation: J Clin Oncol. 2007 Jun 10;25(17):2345-51
references.pmid: 17557947
references.citation: N Engl J Med. 2003 Apr 24;348(17):1625-38
references.pmid: 12711737
references.citation: Breast. 2014 Aug;23(4):435-8
references.pmid: 24836394
references.citation: J Surg Oncol. 2008 Jan 1;97(1):30-4
references.pmid: 17929254
references.citation: J Clin Oncol. 2012 Jan 10;30(2):151-7
references.pmid: 22162577